Boehringer Ingelheim reports positive Phase III RE-VERSE AD study updates of Praxbind

Boehringer Ingelheim has reported positive updated results from its ongoing Phase III RE-VERSE AD study of Praxbind (idarucizumab) to treat patients in emergency settings.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news